Showing 5061-5070 of 9840 results for "".
- Zasocitinib Effective in TYK2 Inhibition for Inflammatory Skin Disease: Studyhttps://practicaldermatology.com/news/zasocitinib-effecgive-in-tyk2-inhibition-for-inflammatory-skin-disease/2474891/Zasocitinib, billed as a 'next-generation' therapy, showed pharmacologic potency and high specificity compared to Janus and other kinase inhibitors, according to new results published in the Journal of Investigative Dermatology</
- Study: Most Global Melanoma Cases Attributable to UV Exposurehttps://practicaldermatology.com/news/study-most-global-melanoma-cases-attributable-to-uv-exposure/2474874/A new global analysis of cutaneous melanoma (CM) shows ultraviolet radiation (UVR) as the primary driver behind the majority of CM cases worldwide in 2022. Researchers used updated incidence estimates from GLOBOCAN 2022 (exclud
- From WHA78: Skin Diseases Are a Global Public Health Priorityhttps://practicaldermatology.com/news/wha78-skin-diseases-are-a-global-public-health-priority/2474881/In what was termed a historic decision at the 78th World Health Assembly (WHA78) in Geneva, Member States unanimously adopted a resolution declaring skin diseases a global public health priority, according to a press statement.
- HADLIMA Cleared for Substitution with Humira in All Forms: FDAhttps://practicaldermatology.com/news/hadlima-cleared-for-substitution-with-humira-in-all-forms-fda/2474836/The US Food and Drug Administration (FDA) has granted full interchangeability status to adalimumab-bwwd (HADLIMA™), a biosimilar of Humira® (adalimumab), across all forms and concentrations, according to a press release from Organon.
- EFFISAYIL 2: Spesolimab Associated with Long-Term GPP Reliefhttps://practicaldermatology.com/news/effisayil-2-spesolimab-associated-with-long-term-gpp-relief/2474835/Patients with generalized pustular psoriasis (GPP) experienced sustained symptom control and quality of life (QoL) improvements when treated with spesolimab, according to an analysis of results from the EFFISAYIL 2 trial. Re
- Concerto Biosciences Completes Data Collection for Massive Skin Microbiome Interaction Projecthttps://practicaldermatology.com/news/concerto-biosciences-completes-data-collection-for-massive-skin-microbiome-interaction-project/2474768/Concerto Biosciences announced today that it has concluded the data acquisition phase of the Skin Universe Project (SUP), collecting over 33 million empirical data points in what it calls the largest known dataset of skin microbial interactions.
- Socioeconomic Disparities Tied to HS Diagnoseshttps://practicaldermatology.com/news/socioeconomic-disparities-tied-to-hs-diagnoses/2474703/Patients living in lower socioeconomic neighborhoods are more likely to be diagnosed with hidradenitis suppurativa (HS), according to a new cross-sectional analysis of data from the University of California San Francisco (UCSF) health system.
- Blended Wavelength Laser Hair Removal Demonstrates Safety and Efficacy Across Skin Toneshttps://practicaldermatology.com/news/blended-wavelength-laser-hair-removal-demonstrates-safety-and-efficacy-across-skin-tones/2474667/New data demonstrates how dual-wavelength laser devices may offer a safer, more inclusive approach to hair removal for all skin tones. At the recent American Society for Laser Medicine and Surgery (ASLMS) annual meeting, Nkemjika Ugonabo, MD, MPH, FAAD, Assistant Professor at Albert Einste
- ElderDerm Co-Director Suggests Alternatives for 'Senile' in Diagnoseshttps://practicaldermatology.com/news/ElderDerm-Co-Director-Suggests-Alternatives-Senile-Diagnoses/2474689/The word senile can be avoided in discussing dermatologic diseases, Jaya Manjunath, MSIV, asserted at the ElderDerm 2025 Conference in Washington, DC. Manjunath, a medical student and co-director of the conference along with Practical Dermatology editorial board member Adam Friedm
- Arcutis Announces Expert Statements on Genital Psoriasishttps://practicaldermatology.com/news/arcutis-announces-expert-statements-on-genital-psoriasis/2474665/Arcutis Biotherapeutics, Inc. has announced new consensus statements aimed at improving the diagnosis and management of genital psoriasis, according to a company press release. The 14 statements, developed by a multidisciplinary group of dermatology and immunology experts with the Genital